Annexon, Inc. Files 2024 10-K
Ticker: ANNX · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1528115
Sentiment: neutral
Topics: 10-K, pharmaceuticals, financials
TL;DR
Annexon's 2024 10-K is in. Details on R&D, warrants, and personnel expenses for the year ending Dec 31, 2024.
AI Summary
Annexon, Inc. filed its 2024 10-K on March 3, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Brisbane, California, operates in the pharmaceutical preparations sector. Key financial activities and disclosures for the period include information on prefunded warrants, personnel expenses, restricted stock units, and research and development expenses.
Why It Matters
This filing provides investors with a comprehensive overview of Annexon's financial performance and operational activities for the fiscal year 2024, including details on its R&D efforts and equity instruments.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Annexon faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The period covered by the 10-K filing.)
- 20250303 — Filing Date (The date the 10-K was submitted to the SEC.)
Key Players & Entities
- Annexon, Inc. (company) — Filer of the 10-K
- March 3, 2025 (date) — Filing date of the 10-K
- December 31, 2024 (date) — Fiscal year end
- Brisbane, California (location) — Company's business address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What is the primary business of Annexon, Inc.?
Annexon, Inc. operates in the Pharmaceutical Preparations sector, with the Standard Industrial Classification code 2834.
When was the 10-K filing submitted to the SEC?
The 10-K filing was submitted on March 3, 2025.
What fiscal year does this 10-K report cover?
This 10-K report covers the fiscal year ending December 31, 2024.
Where is Annexon, Inc. located?
Annexon, Inc. is located in Brisbane, California.
What are some of the financial items disclosed in the filing?
The filing mentions disclosures related to prefunded warrants, personnel expenses, restricted stock units, and research and development expenses.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding Annexon, Inc. (ANNX).